ArticleBiochemical pharmacology2018
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Article in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- An α/β-Hydrolase GmABHD6 Controls Seed Oil Content and Yield in Soybean.Plant biotechnology journal · 2026Article
- Network topology and cannabis use following two weeks of monitored abstinence: moderation of sex and patterns of use findings.Frontiers in adolescent medicine · 2025Article
- N-butyl-β-carboline-3-carboxylate (β-CCB) systemic administration promotes remyelination in the cuprizone demyelinating model in mice.Scientific reports · 2024Article
- Predicting early Alzheimer's with blood biomarkers and clinical features.Scientific reports · 2024Article
- Extracellular vesicles released by microglia and macrophages carry endocannabinoids which foster oligodendrocyte differentiation.Frontiers in immunology · 2024Article
- The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of SativexMini reviews in medicinal chemistry · 2024Review
- The serine hydrolase ABHD6 controls survival and thermally induced seizures in a mouse model of Dravet syndrome.Neurobiology of disease · 2023Article
- Review
- Review
- Reactive chemistry for covalent probe and therapeutic development.Trends in pharmacological sciences · 2022Review
- ABHD6 Inhibition Rescues a Sex-Dependent Deficit in Motor Coordination in The HdhQ200/200 Mouse Model of Huntington's Disease.Journal of neurology and neurological disorders · 2021Article
- α/β-Hydrolase Domain (ABHD) Inhibitors as New Potential Therapeutic Options against Lipid-Related Diseases.Journal of medicinal chemistry · 2021Review
- Heterogeneity of the Endocannabinoid System Between Cerebral Cortex and Spinal Cord Oligodendrocytes.Molecular neurobiology · 2021Article
- Alpha/Beta-Hydrolase Domain-Containing 6: Signaling and Function in the Central Nervous System.Frontiers in pharmacology · 2021Review
- A Critical Review of the Role of the Cannabinoid Compounds ΔMolecules (Basel, Switzerland) · 2020Review
- Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination.Biomolecules · 2020Article
- P2x7 receptors control demyelination and inflammation in the cuprizone model.Brain, behavior, & immunity - health · 2020Article
- Druggable Targets in Endocannabinoid Signaling.Advances in experimental medicine and biology · 2020Review
- Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review.Frontiers in cellular neuroscience · 2020Review
- Glial Cell AMPA Receptors in Nervous System Health, Injury and Disease.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of unknown etiology in which tissue pathology suggests both immune-dependent attacks to oligodendroglia and primary oligodendrocyte demise. The endocannabinoid system has been crucially involved in the control of autoimmune demyelination and cannabinoid-based therapies exhibit therapeutic potential, but also limitations, in MS patients. In this context, growing evidence suggests that targeting the hydrolysis of the main endocannabinoid 2-arachidonoylglycerol (2-AG) may offer a more favorable benefit-to-risk balance in MS than existing cannabinoid medicines. Here we evaluated the modulation of endocannabinoid signaling and the therapeutic potential of targeting the 2-AG hydrolytic enzyme alpha/beta-hydrolase domain-containing 6 (ABHD6) in the cuprizone model of non-immune dependent demyelination. The concentrations of N-arachidonoylethanolamine (anandamide, AEA) and its congener N-palmitoylethanolamine (PEA) were reduced following 6 weeks of cuprizone feeding. Deregulation of AEA and PEA levels was not due to differences in the expression of the hydrolytic and biosynthetic enzymes fatty acid amide hydrolase and N-acylphosphatidylethanolamine-phospholipase D, respectively. Conversely, we measured elevated transcript levels of 2-AG hydrolytic enzymes monoacylglycerol lipase, ABHD6 and ABHD12 without changes in bulk 2-AG concentration. Upregulated CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.